Additional treatment options for SMA are still needed for use in addition to Spinraza, or in place of it for patients for whom it is not suitable, including those with rarer forms of SMA in which SMN1 is not mutated. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.